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Aim: Systemic pharmacotherapies have limitation due to blood-labyrinth barrier, so
local delivery via the round window membrane opens a path for effective treatment.
Multifunctional nanoparticle (NP)-mediated cell specific drug delivery may enhance
efficacy and reduce side effects. Different NPs with ligands to target TrkB receptor were
tested. Distribution, uptake mechanisms, trafficking, and bioefficacy of drug release of
rolipram loaded NPs were evaluated.
Methods: We tested lipid based nanocapsules (LNCs), Quantum Dot, silica NPs
with surface modification by peptides mimicking TrkB or TrkB activating antibodies.
Bioefficacy of drug release was tested with rolipram loaded LNCs to prevent
cisplatin-induced apoptosis. We established different cell culture models with SH-SY-5Y
and inner ear derived cell lines and used neonatal and adult mouse explants. Uptake
and trafficking was evaluated with FACS and confocal as well as transmission electron
microscopy.
Results: Plain NPs show some selectivity in uptake related to the in vitro system
properties, carrier material, and NP size. Some peptide ligands provide enhanced
targeted uptake to neuronal cells but failed to show this in cell cultures. Agonistic
antibodies linked to silica NPs showed TrkB activation and enhanced binding to
inner ear derived cells. Rolipram loaded LNCs proved as effective carriers to prevent
cisplatin-induced apoptosis.
Discussion:Most NPs with targeting ligands showed limited effects to enhance uptake.
NP aggregation and unspecific binding may change uptake mechanisms and impair
endocytosis by an overload of NPs. This may affect survival signaling. NPswith antibodies
activate survival signaling and show effective binding to TrkB positive cells but needs
further optimization for specific internalization. Bioefficiacy of rolipram release confirms
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LNCs as encouraging vectors for drug delivery of lipophilic agents to the inner ear with
ideal release characteristics independent of endocytosis.
Keywords: inner ear, drug delivery, BDNF-TrkB signaling, rolipram, lipid core nanocapsules, polymerosom
nanoparticles, quantum dot nano-suspensions, silica nanoparticle, explant culture
Introduction
Background
The problem of hearing impairment is growing. British MRC
Institute of Hearing Research (www.hear-it.org, 2011) estimates
that the total number of people suffering from hearing
loss of more than 25 dB will exceed 700 million by 2015.
Systemic pharmacological intervention to treat sensorineural
hearing loss suffers to show significant effects. Due to
the demographic development in all western countries age
related hearing loss can be expected to increase continuously
over the next decades. Effective pharmaceutical treatments
are rare.
The isolated anatomical position, a blood-labyrinth barrier
and low blood flow may be reasons that drugs do not reach
therapeutic levels in the inner ear. Local inner ear treatment
via the round window membrane (RWM) seems to be an
effective natural pathway for drug application. Intratympanic
administration of insulin like growth factor 1 (IGF-1) (Nakagawa
et al., 2014) to treat sudden sensorineural hearing loss
shows some promising results, studies of glucosteroids applied
that way differ in their significance (Spear and Schwartz,
2011; Ng et al., 2014). New strategies for preserving low
frequency hearing after cochlear implantation raise growing
needs to protect sensorineural cells from trauma with effective
treatments. There are candidate drugs that show efficacy to
restore damage of the sensory receptor and spiral ganglion
neurons (SGNs). Inhibition of caspases prevents or delays hair
cell death and may preserve hearing/balance function (Wang
et al., 2003; Cheng et al., 2005; Dinh and Van De Water,
2009) and neurotrophic factors have been shown to restore
synaptic connection after noise trauma and promote neuron
outgrowth after deafferenciation (Glueckert et al., 2008) as
well as neural survival (Pettingill et al., 2011). Inhibition or
scavenge of reactive oxygen species is another strategy to
meliorate cell damage (Henderson et al., 2006; Yamasoba et al.,
2013). Another putative therapeutic to provide anti-apoptotic
signaling is rolipram, a posphodiesterase 4 inhibitor which
affects neuronal survival via proteinkinase-A-mediated increase
in cAMP responsive element binding protein activity and the
expression of downstream targets as brain-derived neurotrophic
factor (BDNF) and its high affinity receptor tropomyosin
receptor kinase B (TrkB) (Asanuma et al., 1996; Nibuya et al.,
1996).
Nanoparticle Mediated Drug Delivery (NPDD)
Nanoparticles (NPs) as vehicles to reach target cells in the inner
ear may overcome limitations of pharmaceutical formulations
and specifically target certain cell types. Some drugs show severe
side effects (Suckfuell et al., 2007; Weissmiller and Wu, 2012),
solubility, and stability may be poor (Gupta and Dixit, 2011),
here NPs may act as a versatile tool to avoid off target effects
on healthy tissue. Several NPs have been found to cross the
RWM barrier (Moss and Wong, 2006; Roy et al., 2012; Liu et al.,
2013), this is a prerequisite for atraumatic penetration of the
inner ear. Fluid pathways in the cochlea (Rask-Andersen et al.,
2006; Salt and Plontke, 2009) and in vivo experiments with NPs
showed the feasibility to reach target structures via this route
such as the sensory epithelium and SGNs (Tamura et al., 2005;
Buckiova et al., 2012). Passive diffusion as well as magnetic force
enhancement for paramagnetic NPs was reported to reach at
least the basal portion of the cochlea (Tamura et al., 2005; Ge
et al., 2007; Du et al., 2013). Cell-NP interactions largely depend
on particles’ physicochemical properties including surface
charge, size, shape as well as surface chemistry that builds up
the protein corona with body fluids under in vivo conditions
(Shang et al., 2014) and adds new biological properties.
Multivalent attachment of small molecules or antibodies
adsorbed to the NP surface that interact with membrane
associated proteins may activate cell’s uptake machinery to
internalize the particles. Cell specific internalization with drug
bioefficacy and biosafety of the nanocarrier is the final aim.
Within a European Union Consortium called “NanoEar”
(contract nr. NMP-20043-.4.1.51-1) several NPs were developed
to selectively target sensorineural structures within the cochlea
as vehicles for future pharmacotherapies. Some results are
presented here.
TrkB as Target for NPDD
In the inner ear SGNs are an indispensable element for the signal
transduction from the hair cell to the brain (Bibel and Barde,
2000; Rubel and Fritzsch, 2002). In pathologic conditions, these
cells are prone to cell death. For that reason, the preservation
of those cells is paramount and renders these cells a target
for NPDD. There is a neurotrophic relationship between hair
cells and supporting cells, both providing neurotrophins, and
SGNs, receiving the neutrophins (Zilberstein et al., 2012).
Supplementation of BDNF and neurotrophin 3 (NT-3) after hair
cell loss and subsequent damage to the supporting cells leads to
a higher survival rate of SGNs (Deng et al., 2004; McGuinness
and Shepherd, 2005; Wang and Green, 2011). Especially the
TrkB is of particular interest because as alternative to BDNF,
there is a number of agonistic molecules including antibodies
(Cazorla et al., 2011) that circumvent the low stability of the
BDNF protein. Since TrkB is expressed in adult human SGNs
(Liu et al., 2011) and adult as well as developing mice inner
ears (Bitsche et al., 2011), TrkB is an ideal target for NPDD
targeting the SGNs. On the one hand, TrkB can act as label for
SGNs to mediate specific binding and endocytosis of the NPDD.
On the other hand, TrkB itself can be activated by an agonistic
surface modification and thus contribute to mitogen-activated
Frontiers in Aging Neuroscience | www.frontiersin.org 2 May 2015 | Volume 7 | Article 71
Glueckert et al. Targeted inner ear drug delivery
protein kinase (MAPK), AKT and phospholipase C γ (PLCγ)-
mediated neuronal survival signaling (Klein et al., 1989, 1993;
Minichiello et al., 1998; Atwal et al., 2000; Watson et al., 2001;
Mizoguchi and Nabekura, 2003; Gruart et al., 2007). In parallel
the NPDD is still capable of delivering an anti-apoptotic drug
such as rolipram (Meyer et al., 2012). Co-application of BDNF
and rolipram strongly enhances the survival promoting effect
of BDNF (Kranz et al., 2014). BDNF and rolipram may also
stimulate the pro-apoptotic low affinity p75 receptor in parallel,
so excessive stimulation needs to be prevented, as too much
of pro survival signals may lead to tumorgenesis (Geiger and
Peeper, 2007).
Targeting Ligands
Conjugated targeting ligands and other surface modifications
on NPs serve various purposes like to mediate the permeation
through epithelia, to activate signaling cascades, and to mediate
the specific uptake in distinct cell populations. Ligands include
small molecules, peptides, protein domains, antibodies, and
nucleic acid aptamers, with all classes having unique attributes
reviewed previously (Friedman et al., 2013). Conjugating
targeting ligands such as in terms of surface modifications,
antibodies have already demonstrated in several fields to function
when surface-grafted (Beduneau et al., 2008; Ulbrich et al., 2009;
Choi et al., 2011; Fiandra et al., 2013). For extracellular TrkB
activation, the agonistic anti-TrkB antibody from clone 6B10
(NB110-94149) Novus Biologicals antiTrkB mouse monoclonal
(at 1 mg.ml−1 corresponds to 6.84µM) was used to test TrkB
activation in SH-SY5Y-G7 cells (passage 3). The agonistic anti-
TrkB antibody 29D7 (Wyeth Research, Pfizer, Connecticut, USA)
has already been shown to bind and activate TrkB when surface
grafted to iron NPs (Steketee et al., 2011). Therefore, the use
of 29D7 might be an appropriate means to establish an NPDD
specifically targeting and activating SGN membrane resident
TrkB. Here 29D7 monoclonal TrkB antibody-surface grafted
50 nm silica NPs (aTrkB NP) were used to assess the functionality
of the antibody surface-modification to bind and activate TrkB in
the HEI-OC1 and VOT-N33 cell culture model. The binding of
TrkB by the immuno-NP in the cochlea and the localization after
application was further tested in cochlea whole-organ-culture.
Much smaller than antibodies short homing peptides offer several
advantages such as high packing density, less immunogenicity
and often higher purity, though design can be challenging.
Typically these peptides are identified via the screening tool
phage display (Kehoe and Kay, 2005; Deutscher, 2010), allowing
selection of peptide sequences with increased affinities to a
specific target of choice displayed on bacteriophage capsids that
are collected and amplified with infected E. coli. Numerous
sequences have been tested (Friedman et al., 2013), we designed
peptides based on Ma et al. (2003) and summarized here (Ranjan
et al., 2012).
Material and Methods
Nanocarriers and Ligands
Polymerosomes, lipid core nanocapsules (LNCs), silica as well
as quantum dot NPs (QDotNPs) were used for the presented
study. Peptide ligands are summarized in Figure 5 and described
previously (Ranjan et al., 2012). 29D7 monoclonal anti-TrkB-
antibody was kindly provided by Wyeth Research, Pfizer R©,
Connecticut, USA and characterized previously (Steketee et al.,
2011).
Polymerosomes: Amphiphilic block copolymers can self-
assemble into polymersome NPs in an aqueous environment.
Polymersomes are vesicular, nano-sized spheres that encapsulate
an aqueous solution. The synthetic amphiphilic block
copolymers consist of hydrophilic and hydrophobic units joined
together. Poly lactic/glycolic acid is a charged biodegradable
copolymer composed of lactic and glycolic acid monomers
and forms here Polyethylene glycol-block-polycaprolactone
(PEG-b-PCL) NPs. NP manufacturing and ligand ligation was
described previously (Roy et al., 2010; Pritz et al., 2013b).
Lipid Core Nanocapsule (LNC) structure resembles that
of lipoproteins with a lipidic core (triglycerides, mineral oils)
surrounded by a amphiphilic shell formed by lecithin and stearate
of Polyethlenglycol (PEG), where lecithin is located in the inner
part of the shell. NPs synthesis and characterization is described
here (Bastiat et al., 2013) in detail. Liposomes half-life can be
extended by PEG-derivatized lipids (Uster et al., 1996).
Mesoporous silica NPs display high specific pore volume
and surface area for high drug loadings. Particle size can be
controlled more precisely and functionalization with different
surface modification and tags make them ideal for imaging
purposes. NPs were 50 nm in diameter and manufactured by
MicroMod R©, Rostock Germany and described previously (Pritz
et al., 2013a), FITC fluorochrome served as visualization agent.
29D7 monoclonal anti-TrkB-antibody (Wyeth Research, Pfizer)
surface-grafted silica NPs (42-36-501; S08412, MicroMod R©) and
bovine serum albumin (BSA) surface-grafted silica NPs (BSA-
NP) (42-21-501; S08912, MicroMod R©) were tested.
QuantumDot NPs are made from emulsions, containing iron
oxide, and quantum dots, they are composite NPs composed
of two block copolymers, PLLA-mPEG: Poly(L-lactic acid)-
block-poly(ethylene glycol). We investigated the internalization
efficiency of these particles in neuronal-like cell cultures and
cochlear explants. These NPs were manufactured by the Division
of Functional Materials at the Royal Institute of Technology,
Stockholm, Sweden, are biodegradable and resorbable with a
hydrodynamic diameter of 423 (± 8) nm for orange QDotNPs
and 200 (± 15) nm for green QDotNPs. CdO powder (Fluka)
is added to a mixed solvent system containing 1-octadecene
(Aldrich) and oleic acid (Sigma Aldrich), and heated at 160◦C
under nitrogen for 1 h, to obtain cadmium oleate. This is
stored under nitrogen, and is usable for 2 weeks. Se powder
is added to a mixed solvent system containing TOP (Trioctyl-
phosphine, Fluka) and 1-octadecene and heated at 250◦C
under nitrogen for 1 h, to obtain trioctylphosphine selenide
(TOPSe, Aldrich). This is stored under nitrogen and is usable
for 2 weeks. In a typical synthesis, cadmium oleate is added
to 1-octadecene and oleylamine (Fluka) in a 3-necked flask
and the mixture is heated to 250◦C under nitrogen. At this
temperature, TOPSe is injected into this mixture. Depending
on the desired size of the QDots, this reaction is stopped at
variable times (typically ranging from 20 to 1800 s), by injecting
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excessive amount of solvent at room temperature. QDots are
a very stable fluorochrome and ideal for imaging purposes.
Because of their extremely small size and optical resolution,
they are also well suited for tracking the molecular dynamics
of intracellular and/or intercellular molecular processes over
long time scales (Pathak et al., 2006). Orange Quantum dots:
CdSe/CdS quantum dots (with orange emission) were payloaded
within the NPs, where PLGA: poly(lactic-co-glycolide) is used
as a matrix material and carboxylic group as a surface. Green
Quantum dots: CdSe/CdS quantum dots (with green emission)
were payloaded within the NPs, where PLLA-mPEG: poly(L-
lactic acid)-block-poly(ethylene glycol) is used as a matrix
material and PEG as a surface. Characterization of CdSe quantum
dots: A sample of NP suspension is characterized by ultraviolet
and visible spectroscopy, and photoluminescence spectroscopy
by depositing 1ml of suspension in a polymethyl methacrylate
cuvette at room temperature. Transmission electron microscope
(TEM) analysis was performed after depositing one drop of NP
suspension on a copper grid coated with formvar and carbon and
letting to dry.
Cell Culture
HEI-OC1 cells were isolated by Dr. Federico Kalinec (Yorgason
et al., 2010) and are used as a model for TrkB positive cells
in the inner ear, when cultured under 33◦C and 10% CO2.
Furthermore, after differentiation at 39◦C and 5% CO2 these
cells represent a model for inner and outer hair cells of the
mouse cochlea. Cells were grown as described previously (Pritz
et al., 2013a). For size dependent uptake cells were plated on
21 × 26mm cover slips. The cover slips were placed into 6-
well plates; cells were plated at 104/ml. NP treatment occurred
usually 24 h after plating. NPs were used in 500-, 1500- and
15,000- fold final dilution. For antibody coated silica NPs cells
were plated 12 h before the start of the experiment. Cells were
incubated with 9.5 × 109 NP.ml−1 29D7 monoclonal TrkB-
antibody (Wyeth Research, Pfizer) surface-grafted silica NPs
(42-36-501 S08412, MicroMod R©, Rostock Germany) and BSA
surface-grafted silica NPs (42-21-501 S08912, MicroMod R©).
Each particle type was tested in two different conditions creating
a competitive assay: binding and blocking conditions. Binding
conditions: Cells were incubated with NPs at pH 7.4 in serum-
free conditions in Dulbecco’s Modified Eagle (DMEM) low-
glucose Medium (E15-005 PAA Pasching, Austria) for 90min.
Blocking conditions: Cells were incubated with NPs at pH7.4
together with free 29D7 monoclonal TrkB-antibody (Pfizer R©,
USA) in 1 nM concentration (63-fold excess) for 90min. The
experiment was carried out at 4◦C to prevent endocytosis and at
33◦C the culturing temperature of the cells to permit endocytosis.
According experiments were performed with BSA-grafted silica-
NPs under same conditions. In each group 15–20 cells were
analyzed.
The auditory neuroblast cell line US/VOT-N33 (N33), which
is conditionally immortal, was kindly provided by Matthew
Holley and shall serve as an in vitro model for SGNs. Culture
conditions were described previously (Nicholl et al., 2005). In
brief, cells are grown in minimum essential medium (MEM)
containing 10% fetal calf serum at 33◦C, 10% CO2 and after 3 h
serum deprivation used for experiments. Antibody coated silica
NPs were applied like with HEI-OC1 cells.
The neuroblastoma cell line SH-SY5Y was differentiated by
all-trans-retinoic acid (ATRA) treatment that induces expression
of TrkB, but not of TrkA receptor, and mediates biological
responsiveness to receptors for the neurotrophins BDNF andNT-
4/5 as described previously by our group (Ranjan et al., 2012).
As an alternative to SH-SY5Y cells, stable TrkB-transfected
G7 cells were received from Garrett Brodeur, M.D. (Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania, USA) and
maintained and cultured as referenced (Eggert et al., 2002). TrkB
overexpressing SH-SY5Y cells were grown in the presence of
the selection antibiotic as described elsewhere (Soumen et al.,
2012). Cells were plated 12 h before the start of the experiment.
Cells were serum starved for 3 h. Then cells were incubated
with 5.5 nM BDNF, 1.9 × 1010 NP.ml−1 immuno-NP, 1.9 ×
1010 NP.ml−1 immuno-NP and 9.5 × 109 NP.ml−1 BSA-NP
for 90min. Cells were rinsed three times in Tris-buffered saline
(TBS) buffer and subsequently harvested with a cell scraper
and lysed in lysis buffer (1% v/v NP-40, 50mM Tris pH 8,
150mM NaCl, 5mM ethylenediaminetetraacetic acid (EDTA)).
Protein quantification was subsequently performed by a Bradford
assay (500-0001, BioRad, Vienna, Austria), at 595 nm using a
BioPhotometer Plus (Eppendorf R© Germany, Wien, Austria).
Western Blotting
Fifteen microgram of protein lysate was loaded in each slot.
SDS-PAGE was carried out at 20mA for 1 h in a 12%
bisacrylamid gel using a Mighty Small II Deluxe Mini Vertical
Electrophoresis Unit (SE260, Hoefer, Holliston, USA). Protein
was subsequently transferred to a PVDF membrane (88518,
Thermo Scientific R©, Waltham USA) using a Maxi-BlotTank
fully wet blotter (340.000, GP Kunststofftechnik, Germany)
at 60mA for 4 h at 4◦C. Membranes were subsequently
stained with anti-phospho-Erk1/2 antibody (#9101 Cell Signaling
Technologies) in 1:1000 dilution and goat anti rabbit horseradish
peroxidase (HRP) conjugated (31460, Thermo Scientific R©) in
1:10 K dilution as described in detail in Wiedemann et al.
(2006). Signal detection was performed by enhanced chemi-
luminescence using SuperSignal West Dura Chemilumenescent
Substrate (37071,Thermo Scientific R©) and CL-Xposure X-
Ray films (34091, Thermo Scientific R©). X-Ray films were
subsequently scanned.
Organotypic Culture and Zero-gravity Whole
Organ Culture of the Cochlea
Organotypic mouse culture was performed on neonatal P1–
P3 mouse cochleae as described previously (Roy et al., 2010).
Zero-gravity whole organ culture of adult cochlea was done
with P18–P30 mice anesthetized by intraperitoneal injection
of ketanmin hydrochlroid (84µg.g−1 bodyweight, Ketasol R©
Graeub Veterinary Products, Bern Switzerland), 0.25µg.g−1
bodyweight atropine sulfate (Atropium Sulfaticum, Nycomed R©
Austria GmbH, Linz, Austria), and 6.7 mg.g−1 bodyweight
xylazin (Bayer R© Healthcare, Berlin, Germany) in physiologic
saline and subsequently killed by cervical dislocation. The
cochleae were removed from the scull. All animal experiments
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were approved by the Austrian Ministry of Science and Research
and conformed to the Austrian guidelines on animal welfare
and experimentation (BMWF-66011/0109-II/3b/2012). Stapes,
RWM as well as the bone covering the apical portion of the
cochlea and 270◦ along the basal turn covering the scala tympani
was removed. The dissected cochleae were then transferred
to culturing medium pre-warmed to 37◦C. The culturing
medium was composed of 100 U.ml−1 penicillin (P7794-10MU,
Sigma Aldrich, Vienna, Austria), B27 supplement (17504044,
Invitrogen, Lofer, Austria), 5mM L-glutamine (BE 17-505E,
Lonza), Neurobasalmedium (21103-049, Invitrogen) at pH 7.4.
The culturing was performed in a rotary cell culture system
(RCCS-4SC, Synthecon R© Incorporated, Housten, USA) in 10ml
disposable HARV-10 vessels (Synthecon R© Incorporated) for 2 h.
The culturing medium was then supplemented with 9.5 × 109
aTrkB NPs for immuno-conjugate NPs for 24 h or LNC particles
loaded with rolipram as described by Meyer et al. (2012). LNCs
were provided in a concentration of 4 × 1015 particles/ml with a
hydrodynamic diameter of 52 ± 5 nm. 1:100 and 1:1000 dilution
of LNC particles loaded with 2µM rolipram with adding 50µM
cisplatin to the culture medium were tested in comparison with
50µM cisplatin and culture medium alone for 24 and 48 h.
Processing of Cultured Cochleae
After culturing, cochleae were washed in phosphate buffered
saline (PBS) and subsequently fixed in 2% paraformaldehyde in
PBS overnight at 4◦C. The specimens were decalcified using 20%
EDTA in PBS for 4 h at 37◦C. Specimens were then infiltrated by
in an ascending series of 10 and 15%D-sucrose in PBS, and finally
a mixture of 15% D-sucrose and 50% OCT-compound (4583,
Tissue-Tek R©, Finetek Sakura R© Europe, Leiden, Netherlands).
Final infiltration was performed in 100% OCT R©-Compound
overnight. Cochleae were rapidly frozen in OCT R©-compound
at –78◦C as in a 1 + 1 EtOH:dry ice mixture. One half of
the frozen cochleae were subsequently cryo-sectioned in 10µm
sections. The other half of the cochleae were thawed and post
fixed in 2% glutaraldehyde in PBS at pH 7.4. Cochleae were than
incubated in 1% OsO4 for 1 h at 4
◦C in 0.05M cacodylate buffer.
Specimen were then dehydrated in an ascending EtOH series and
embedded in Epon 812 (Electron Microscopy Science, Hatfield,
UK, 14120) as described elsewhere (Thaler et al., 2011; Pritz et al.,
2013a).
Immunostaining
Cell culture: early endosome antigen (EEA1) and lysosomal-
associated membrane protein (LAMP-1) staining was performed
as described previously (Pritz et al., 2013a). Rotary culture
sections: After 3 × 5min in PBS blocking and permeabilization
(1 h 1% BSA and 5% normal goat serum in PBS + 0.05%
Tween 20 at 4◦C) primary antibodies rabbit-anti cleaved caspase-
3 (CC3) 1:400, (Asp175, Cell signaling 9661L) Abcam R© rabbit
polyclonal anti-beta-III-Tubulin ab 1:200 or rabbit IgG isotype
control was applied for 1 h at 4◦C. After thorough wash in
PBS, 2nd antibody Alexa R© Fluor 647 F(ab’)2 fragment goat
anti rabbit (111-606-047, Jackson Immunoresearch R©, PA, USA)
1:1500 in 0.5% (w/v) BSA was incubated overnight at 4◦C in dark
and subsequently 30min 37◦C and mounted with Vectashield R©
including DAPI (Vector Laboratories R© Ltd, UK). Phalloidin
FITC (Sigma R© P5282; 1:80) was applied according to the
manufacturer’s protocol. Control samples were substituted with
isotype matching rabbit immunoglobulins (rabbit polyclonal
IgG Abcam R©, ab27478, 1:200). These controls were consistently
negative.
Confocal Microscopy
NP treated cells were illuminated by a 488 nm laser, at pinhole
= 3 AU, resulting fluorescence was collected between 505 and
545 nm. Cochlea sections and NP treated cells were examined
using Zeiss R© LSM510 Meta (Zeiss R©, Oberkochen Germany)
using ZEN 2009. FITC was excited by 488 nm laser. For pairwise
comparison of NP binding cells were imaged with a pinhole of
3 AU, illumination by a 488 nm laser, resulting fluorescence was
collected from 505 to 545 nm. Due to the high autofluorescence
in adult cochlea explant sections, the FITC in NPs was detected
using lambda stacks from 490 to 700 nm. To distinguish FITC
fluorescence from autofluorescence ratiometric detetection was
performed. Fluorescence at 520 nmwas divided by 565 nm. Alexa
647 was excited with a 633 nm Laser and detected with 650
bandpass filter, DAPI excited with 405 nm laser as described
previously (Glueckert et al., 2008).
Transmission Electron Microscopy
For electron microscopy, epon blocks were sectioned to 80 nm
sections. Electron microscopy was performed using a Zeiss R©
Libra 120 EFTEM (ZEISS, Oberkochen, Germany) as described
in Pritz et al. (2013a) and Thaler et al. (2011).
Flow Cytometry
SHSY5Y cells were grown in DMEM/F12 1:1 medium (PAA,
Linz, Austria) supplemented with 2mM L-glutamine, penicillin
(20 units/ml), streptomycin (20mg/ml), and 15% (v/v) heat-
inactivated fetal calf serum (PAA R©) (Ranjan et al., 2012). Cells
were maintained at 37◦C in a saturated humidity atmosphere
containing 95% air and 5% CO2. Cells were seeded at an initial
density of 104 cells/cm2 in culture dishes (Unilab R©, Innsbruck,
Austria). All-trans-RA (Sigma R©, Darmstadt, Germany) was
added on the day of plating at a final concentration of 10µM
in DMEM/F12 with 15% fetal calf serum, and after that, daily.
After 5 days in the presence of ATRA, cells were treated with LNC
nanoparticles at 50µg/ml final concentration for 5 or for 24 h,
and analyzed by flow cytometry. The prepared LNCs contained
Nile Red, which was used as a model of amphiphilic carried
drug, and was also detectable by the excitation of the 488 nm
laser source in flow cytometry. The particles were prepared
without peptide conjugate and with A415, A747, scrambled
Scr-A415, and scrambled Scr-A747 peptides, where A415 and
A747 were intended as TrkB-targeting peptides, the other two
were synthesized with scrambled sequences. The hydrodynamic
diameter of the particles ranged 49–58 nm (Figure 5). LNCs
labeled with Nile Red were intact particles in flow cytometer
within the 24 h of experimentation. After the desired incubation
period, cells were removed and collected from the culture
dishes by trypsinization (PAA R©) washed once with serum-
containing culture medium and resuspended with Isoton II
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sheath (Beckman Coulter R©, Brea CA, USA) at 106 cells/ml
sheath. Cell suspension was observed using a Coulter R© XL-MCL
flow cytometer (Beckman Coulter R©) using the FL-2 channel
with excitation of 488 nm and detection of the emission at 560–
590 nm. These conditions are optimal for detecting Nile Red in
lipid environment, as expected in LNCs (Greenspan and Fowler,
1985). Not stained cells were used as control and showed 0.9–
2.1% Nile Red-like signal. These events were used for gating
cells in the forward-side scatter scattergrams. The forward-side
scatter scattergrams of LNC-incubated cells were comparable
with the controls. The FL-2 signal of the LNC-treated cells has
shown an increase. Percentage of cells showing increased signal
(above the control level) was determined by the software Expo 32
(Coulter R©), and was considered as Nile red positive cells.
Statistical Analysis
Experiments were planned as pair wise comparisons between
binding and blocking conditions. When normal distribution
was detected using Kolmogorov-Smirnov test, unpaired t-test
was used at an alpha of 5%. When data was not normally
distributed and transformation with monotonous functions
failed to transform to normal distribution non-parametric tests
were used.
Results
NP Uptake in Cochlear Tissue
The interface of LNCs, a highly packed monolayer of surfactants,
has been modified by the post-insertion process carried out with
pegylated amphiphilic phospholipids. This assay allowed us to
introduce reactive amino groups on the surface, easily grafted
with Rhodamine B molecules in the matrix material and was
applied at a final concentration of 6.45 × 1014 particles/ml.
Figures 1A,B shows the concentration gradient in different cell
types in an organotypic culture of a mouse inner ear 3 days
postnatal (P3). Penetration into the cytoplasm was observed all
over the explant but enhanced staining was seen in the region
of the SGNs, no signal was detected in any cell nuclei. Not
the big bipolar neurons but smaller surrounding cells show
highest uptake corresponding to satellite glia cells (SGC) that
migrate from the neural crest to ensheath all neurons at a
later stage of inner ear development. Figure 1C illustrates the
anatomy of SGNs in a plastic embedded tissue with incomplete
sheath of SGC. This depicts some selective nature of these LNC
particles to show a preference for a certain cell type at a certain
developmental stage.
Size-Dependent Internalization
NP size has a big influence on uptake kinetics and cell type
selectivity. We tested different polymerosom NPs with zeta ξ
potential = 1mV and different mean hydrodynamic diameter
(MHD) such as N115 (MHD = 70.2 nm), N116 (MHD =
91.2 nm) and N117 (MHD= 111.6 nm) in a concentration range
in between 0.05 and 0.25mg/ml with the different incubation
time like as 2, 4, 6, 12 and 24 h in organotypic cultures of P1–
P3 mice as described previously (Roy et al., 2010). Uptake of NPs
was seen in an increasing time dependent manner from 2 to 24 h
(Figure 2).
FIGURE 1 | 50nm Rhodamin labeled LNC NPs without any surface
functionalization after 24h incubation in an organotypic cochlear
culture (A,B confocal projection). Panel (A) shows higher uptake in in the
region of the spiral ganglion neurons (SGN). Panel (B) is a magnified view of
the SGN region and identifies small cells surrounding the neurons (asterisks)
with intense staining. Panel (C) corresponds to this region in a semithin section
with big type I neurons (asterisks) and satellite glia cells (arrows) that establish
the glia sheath of neuron somata. SLI, spiral ligament; OC, organ of Corti; PNF,
peripheral nerve fibers. Scale bars (A) 50µm; (B) 20µm; (C) 20µm.
For a more detailed analysis we performed this experiment
with LNCs in a size range of 25–100 nm in HEI-OC1 cell
lines for 12 h in different dilutions of NPs (Figure 3). FITC
was incorporated in the shell, neither payload nor ligand was
added. After 12 h incubation in different dilutions of LNC25
(MHD= 25.2 nm), LNC50 (MHD= 53.39 nm), LNC100 (MHD
= 102.9 nm), every NP tested showed most uptake in 1:200
dilution (see Figure 3). Further, the LNC25 was internalized
most efficiently. The differences in uptake were even statistically
highly significant at 200 fold dilution of NPs (LNC25 vs. LNC50
p < 0.001; LNC25 vs. LNC100 p < 0.001; LNC50 vs. LNC100
p = 0.004, Rank-Sum test, nsmall = 12). In 1500 and 15,000
fold dilution no statistical significant difference in uptake could
be observed.
Big QDotNPs (Figure 4) were rather selectively found within
cells in the spiral ganglion of organotypic cultures (P3). QDot
orange as well as QDot green was located within the cytoplasm
of cell somata of putative SGCs and SGNs (Figure 4B) and
some cells in the sensory epithelium (arrowhead, Figure 4A),
likely macrophage like cells. This result was surprising and
suggests an interaction of QDotNPs with neuronal cells at
that developmental stage. Since we tested only in an immature
model we cannot predict SGNs behavior with mature-by SGC
ensheathed-neurons in adult tissue.
Ligand Functionalized Nanocarriers
Small peptides with theoretical binding affinity for TrkB receptor
(Figure 5C) were tested for specific binding and payload release
(Nile red) with LNCs. After 5 days of ATRA treatment SHSY5Y
cells were treated with LNC nanoparticles at 50µg/ml final
concentration for 5 or for 24 h, and analyzed by flow cytometry.
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FIGURE 2 | Size dependent uptake of polymerosom NPs of different
hydrodynamic diameter (N115 = 70nm, N116 = 91nm, N117 =
112nm) in P3 mouse organotypic culture from 2 to 24h of incubation:
smallest particles show uptake within 2h while biggest need 6h. Scale
bar 200µm, (A–E) 70 nm , (F–J) 91 nm, (K–O) 112 nm particles exposed for
2 h (A,F,K), 4 h (B,G,L), 6 h (C,H,M), 12 h (D,I,N) and 24 h (E,J,O).
FIGURE 3 | Size-dependent internalization of unfunctionalized
FITC-loaded LNCs in HEI-OC1 cells. (A) Bar chart classifies 25 nm-sized
NPs to be internalized most efficiently while 100 nm LNCs were internalized with
the least efficiency (**p < 0.01, ***p < 0.001, ANOVA, error bars denote
standard deviation). 200–1500 times dilution of LNCs shows significant
differences. (B–D) Representative examples of HEI-OC1 cells treated with
FITC-loaded LNCs (200 times dilution); diameter of LNCs is denoted in the
upper right of the micrograph. Green fluorescence is FITC from LNCs, blue
fluorescence is DAPI, scale bars 10µm.
The unconjugated LNC particles were detectable in almost all
cells after 5 h (Figures 5A,C), which decreased to 77% of the cells
after 24 h (Figures 5B,C). The peptide conjugated LNC particles
were detected in 21–25% of the cells after 5 h and in 43–67% of the
cells after 24 h (Figures 5A–C). The targeting or control sequence
of the peptide did not have significant effect on the detection
of Nile Red in the cells (p > 0.05, with One-Way ANOVA).
Surface functionalization hampered NP/payload uptake in this
cell line, peptide sequence did not show a significant effect. This
suggests a peptide sequence independent uptake of LNC particles
in SHSY5Y cells. Five hour treatment: Data were not normal
distributed using theD’Agostino and Pearson omnibus normality
test. Comparison of LNC with A415 with LNC with Scr-A415
using Mann-Whitney U-test: p = 0.1242.
Twenty four hour treatment: Data were not normal
distributed using theD’Agostino and Pearson omnibus normality
test. Comparison of LNC with A415 with LNC with Scr-A415
using Mann-Whitney U-test: p = 0.100.
A415 ligand conjugated polymerosom NP (FITC in the shell)
incubated in cochlear explant cultures for 24 h showed some
specifity for neuronal cells in the spiral ganglion (Figures 6B,C),
while scrambled peptide showed same specifity but less uptake
(Figure 6D, not quantified). Plain polymerosomes showed an
even distribution of cellular uptake (Figure 6A). Also in this
experiment small peptides change the uptake specifity, here a
directional uptake into neurons is visible.
Extracellular-activated Kinase Activation with
Agonistic TrkB Antibody
In order to assess, the capability to activate TrkB-downstream
signaling with an agonistic anti-TrkB antibody, the ERK
phosphorylation was assessed by western blotting of treated
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FIGURE 4 | Internalization of plain bigger QDot NPs shows selectivity for cells in the spiral ganglion (SG) in organotypic cultures with QDot orange
(A,B) and QDot green NPs (C). Panel (B) is a higher magnified view of (A) that confirms NPs within the bigger spiral ganglion neuron cytoplasm.
FIGURE 5 | Flow cytometry results of LNC NP uptake of functionalized
TrkB targeting ligands (A415, A747) and scrambled control ligands
(Scr-A415, Scr-A747) in comparison with unfunctionalized LNCs after
5 h (A) and 24h (B) incubation. Nile Red payload is detected in percentage
of positive cells, the table in (C) summarized peptide sequence,
hydrodynamic NP diameter and quantitative flow cytometry data.
TrkB-overexpressing SH-SY5Y G7 cells. Phosphorylated ERK1/2
from SH-SYS5 G7 cells treated with 10 nM BDNF, 10 nM
antiTrkB (6B10) and untreated were compared. After 30min
incubation with antiTrkB, slight ERK1/2 phosphorylation is
visible (Figure 7A, Table 1). The phosphorylation is lower than
observed with cells treated with 10 nM BDNF but clearly above
the basal phosphorylation level.
Silica NP conjugated to 29D7 agonistic antibody (aTrkB
NP) also showed effective neurotrophic signaling (Figure 7B).
TrkB overexpressing SH-SY5Y G7 cells were treated with 5.5 nM
BDNF, 1.9 × E10/ml aTrkB NPs, 1.9 × E9/ml aTrkB NPs and
1.9 × E10/mL BSA-linked NPs. 1.9 × E10/mL. aTrkB NPs were
able to induce a phosphorylation response comparable to BDNF.
When aTrkB NPs were diluted 10-fold the phosphorylation
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FIGURE 6 | Organotypic culture with A415 peptide functionalized
polymerosom NPs after 24h of incubation.While plain LNCs shows even
distribution (A), A415-LNC; (B,C) and scrambled A415(scr-A415-LNC); (D)
reveal aggregation in the spiral ganglion (SG) region. Higher magnified view in
(C) reveals signals mainly within bigger type I neurons. Phalloidine staining (red)
indicates stereocilia positions within the sensory epithelium.
efficiency dropped to the level of the BSA grafted control
particles.
When cells were treated with 5.5 nM BDNF (equals
100 ng.ml−1) strong phosphorylation of ERK was induced
(Figure 7B). A similarly strong phosphorylation was induced by
1.9× 1010 NPs.ml−1 NPs, which carry agonistic TrkB antibodies
on their surface immuno-conjugated NP. BSA coated control
particle at a concentration of 1.9 × 1010 NP.ml−1 were not able
to induce a similar magnitude of ERK phosphorylation. Also
a 10-fold dilution of the aTrkB NPs resulted in a lower ERK
phosphorylation (Figure 7B, Table 2).
Agonistic TrkB Antibody Binding Tests
Assessment of the binding capability of our immuno-conjugated
NPs was performed in competitive assays (Figures 8A–F).
Cells were exposed to aTrkB NPs alone, allowing specific and
unspecific binding (Figure 8A) and in a competitive assay with
inhibiting specific antibody-mediated binding of the aTrkB NP
by an excess of free antibody (Figure 8B). When the experiment
was performed at 4◦C (Figures 8C,D), preventing endocytosis,
under binding conditions, there were significantly more (p =
0.001, rank-sum test) NPs attached to the cells than under
blocking conditions (Figure 8C). No statistical difference (p =
0.450, rank-sum test) was observed when the experiment was
performed under identical conditions using BSA-NPs instead of
aTrkB NPs (Figure 8D). This suggests an involvement of the
antiTrkB-surface modification in the binding of the immuno-
conjugated NP. When the experiments were performed at 33◦C
(Figures 8E,F), allowing endocytosis, there were more aTrkB
NPs found to be associated with the cells than under blocking
conditions (Figure 8E). However, difference was not significant
(p = 0.126, rank-sum test). Using control BSA-NP, no significant
difference (p = 0.142, rank-sum test) between binding and
blocking conditions was observed (Figure 8F). These results
suggest that under given conditions the surface modification
is not playing a significant role for the endocytic uptake of
immuno-conjugated NPs.
Trafficking of Antibody Conjugated Nanoparticles
aTrkB NPs were also tested for internalization and subcellular
localizations in HEI-OC1 (Figures 9A–H) and VOT-N33
(Figures 9I–P) cells. In both cell lines NPs were found in
early endosomes outlined by EEA1 (Figures 9B,J) as well as
in LAMP1 (Figures 9F,N) positive late endosomes/lysosomes.
After 1 h of incubation aTrKB-NPs localize in EEA1 positive
endosomes in both cell lines and after 90min in LAMP1 positive
late endosomes/lysosomes (Figures 9A–H). Like reported
previously with unfunctionalized silica NPs (Pritz et al., 2013a)
NPs ended in large endosomes with non-overlapping intensity
maxima of NP and endosomal marker (Figures 9L,P). We found
unfunctionalized silica NPs surrounded by big LAMP-1 positive
“rings” to resemble single-membrane compartments with
multiple particles at TEM level. Since also in these experiments
with aTrKB-NPs few NPs were observed in small vesicles, so
clathrin or caveolin mediated endocytosis may be low. The big
(>500 nm up to severalµm) LAMP-1 positive vesicles resemble
macropinosomes like we found with unfunctionalized particles
at TEM level previously (Pritz et al., 2013a). This suggests
that macropinocytosis may be a dominant uptake mechanism,
further no evidence for endosomal escape of these nanocarriers
was found.
Rotary Culture of NP-treated Inner Ears
When whole-organ-cultures were treated with aTrkB NPs for
2 and 8 h, NPs were found to be distributed throughout the
cochlea. NPs were observed in the mesothelial/mesemchymal
cells lining the perilymphatic fluid spaces. Dense agglomerations
of immuno-conjugated NPs were found in the mesothelial layer
of Reissner’s membrane (Figure 10A) and tympanic covering
layer cells underneath the basilar membrane. Infrequently, the
aTrkB NPs were observed in the organ of Corti (Figures 10A,B)
especially in inner hair cells (Figure 10B) and even less frequently
the immuno-conjugated NPs were observed in the spiral
ganglion (not shown). In order to overcome the limitations
in spatial resolution of light microscopy electron microscopy
was performed (Figure 10C). Ultrathin sections were screened
for functionalized silica NPs. NPs were found to localize
within tympanic covering layer cells of the basiliar membrane
(Figure 10C). However, both outer and inner hair cells were
not associated with NPs investigated at ultrastructural level. The
basal pole of hair cells, where TrkB is exposed by the synaptic
terminals, was not found to be associated with NPs. Also the
endosomal compartment of hair cells was devoid of aTrkB NPs
(not shown). Neither near nerve fibers in the lamina ossea spiralis
nor within SGNs were particles detected at ultrastructural level.
Based upon these observations, quantitative delivery to TrkB-
positive cells such as SGNs and hair cells is very unlikely although
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FIGURE 7 | ERK phosphorylation with anti-TrkB-antibody and
anti-TrkB-antibody-functionalized silica NPs (aTrkB-NPs). (A)
Agonistic anti-TrkB antibodies (6B10) without NPs applied to
TrkB-overexpressing SH-SY5Y G7 cells induces ERK phosphorylation
equivalent comparable to 5.5 nM BDNF application (10 nM BDNF
shown). (B) Semi-quantitative comparison of ERK-activation by
aTrkB-NPs (29D7) within TrkB-overexpressing SH-SY5Y cells compared
to BSA-functionalized NPs: aTrkB-NPs in 1000-fold dilution elicited a
similar activation of ERK as observed with 5.5 nM BDNF while
BSA-functionalized NPs did not. At 10,000 fold dilution there is no
significant difference to basal phosphorylation level. Western blot data
are shown below.
TABLE 1 | Densitometric analysis SH-SY5Y G7 treated with anti-TrkB
(6B10) antibody vs. BDNF presented as ratio over GAPDH expression.
Treatment Mean density Mean density Ratio over
GAPDH pERK GAPDH expression
Anti-TrkB (6B10) 35.002 24.5 0.699960002
BDNF 10 nM 30.477 83.345 2.734685172
Control 39.028 4.14 0.106077688
TABLE 2 | Densitometric analysis SH-SY5Y G7 treated with anti-TrkB
(29D7) conjugated silica NP vs. BDNF presented as ratio over GAPDH
expression (N = 4).
Treatment Mean-pERK to GAPDH SD pERK-related GAPDH
BDNF 5.5 nM 0.882019403 0.096842924
aTrkB NPs 1 k fold 0.972157927 0.130999313
aTrkB NPs 10 k fold 0.349104961 0.084694112
BSA-NP 1 k fold 0.698961261 0.00317995
some aggregation in inner hair cells is apparent at confocal level
that conforms with TrkB expression in adult mice inner ears
(Bitsche et al., 2011). Immunostaining of control adult inner ear
cultures affirms the presence of an intact and innervated sensory
epithelium (Figure 10D).
Rescuing SGNs with Rolipram-Loaded LNCs
Scheper and Colleagues demonstrated (Meyer et al., 2012)
that rolipram-loaded LNCs can be used to prevent apoptosis
of SGN culture. Here, we employed postnatal rotary culture
of whole inner ears to test the potential of rolipram-loaded
LNCs in a controllable environment. Rotary culture allows
controlling both inducing apoptosis by chemical reagents
and the treatment by NPs in controlled concentrations.
In our model, we induced apoptosis by the application
of 50µM cisplatin (Figure 11). In cisplatin-treated cochleae,
we observed a rise in CC3 immunoreactivity after 24 h
of treatment (Figure 11D). However, when rolipram-loaded
LNCs diluted 1000-fold applied together with cisplatin, the
CC3 immunoreactivity was significantly reduced (Figure 11A).
Analogous to the SGN similar effects were observed in the
spiral ligament, which appears to be susceptible to apoptosis
in the, cochlea culture. In this part of the cochlea, CC3
levels could also be rescued by the application of rolipram-
loaded LNCs (Figures 11G,J). Controls are summarized in
an Supplementary Figure 1. Together, this demonstrates that
mouse rotary cultures of the cochlea is an efficient and
sensitive test bed for the pharmacotherapy of the NPs. The
rotary culture allows for exact control of concentration of
reagents. It excludes the detrimental influence of animal behavior
and is perfectly compatible with imaging-based analysis and
biochemical interrogation.
Discussion
In the present study we demonstrated some principle application
of nanocarriers for use of drug delivery to the inner ear. NP
size influences uptake kinetics and may reflect different pathways
into the cells. Mironava et al. reported that 45 nm Gold NPs
penetrate dermal fibroblasts via clathrin-mediated endocytosis,
while smaller 13 nm Gold NPs enter mostly via phagocytosis
(Mironava et al., 2010). Mesoporus silica NP showed maximum
uptake at a NP size of 50 nm; 30 and 110 nm showed significantly
less uptake by HeLa cells (Lu et al., 2009). A NP core size of 30–
50 nm seem to be an optimal size for active uptake (Shang et al.,
2014) for most cells. Small spherical NPs have less interaction
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FIGURE 8 | Assessing the functionality of agonistic anti-TrkB
(29D7)-surface grafted silica NPs (aTrkB-NP). Principle of
competitive binding assays: (A) Under binding conditions, aTrkB-NPs
are able to specifically und non-specifically bind to the cells. (B)
Under blocking conditions the excess of free antibody should avoid
the specific binding of the aTrkB-NPs leaving only non-specific
interactions for binding. In theory a functional antiTrkB surface
modification should lead to significantly higher binding and uptake of
NPs under binding conditions. Panels (C–F) pairwise comparisons of
blocking and binding conditions in HEI-OC1 cells. (C) HEI-OC1 cells
incubated with aTrkB-NPs at 4◦C, preventing endocytosis, showed
significantly more binding under binding conditions (p < 0.05, rank-sum
test). (D) The same experiment performed with BSA-NP did not show
a significant difference (p > 0.05, rank sum test). (E) When the
experiment was performed at 33◦C, allowing endocytosis, no difference
between binding and blocking conditions was observed (p > 0.05, rank
sum test). (F) The application of BSA-NPs resulted in no difference
(p > 0.05, rank sum test).
with the cell membrane, so small NP have to aggregate at the
cell surface to trigger internalization (Jiang et al., 2010). Although
we controlled NP composition and charge and used serum free
media supplements, the NP corona will have been altered by
some of these supplements and proteins secreted by cells and
inner ear explants. Therefore, we can only speculate on uptake
mechanisms varying with NP size. For unfunctionalized 50 nm
silica particles we found macropinocytosis to be most relevant
privileged by in vitro formation of NP agglomerates (Pritz et al.,
2013a) and confocal imaging on the TrkB functionalized here
show similar results. NP aggregation under in vitro conditions
is poorly understood. Material properties such as particle size,
morphology, and crystallinity are important parameters affecting
nanoparticle colloidale stability (Gambinossi et al., 2014). The
impact of aggregation cannot not easily predicted and needs to
be evaluated NP by NP. Unfunctionalized LNCs highly penetrate
cells and tissue of the inner ear and are able to release their
cargo such as rolipram. LNCs are chemically stable and ideal
to encapsulate hydrophobic cargos at high encapsulation rates.
They displayed clear size dependency of internalization and did
not show signs of toxicity compared to control experiments.
In cochlear explants an enhanced uptake was identified for
immature SGCs. Like in dorsal root ganglia there are cells to
migrate from the neural crest and have the potential to generate
glia and more than 20 different neuronal cell types, many of
these cells undergo apoptosis (Raible and Ungos, 2006). The
cells responsible for dead dorsal root ganglia neurons removal
are satellite glial cell (SGC) precursors, rather than macrophages
(Wu et al., 2009). These characteristics might be valid also
for SGC in the immature cochlea and may explain enhanced
uptake. Polymerosomes confirms that size is an important factor
for kinetics of tissue penetration. On the big end of our NP
portfolio QDot NPs demonstrated that also particles of several
hundreds of nm show capability for uptake in SGCs and
SGNs. Although we clearly found these particles also in the
bipolar neurons uptake by immature SGCs and transcytosis to
SGN may occur here, especially with those neurons that are
already completely covered by their satellite sheath. Further,
analysis might be valuable to study this possible pathway of NP
transport.
As NPs are functionalized with small peptides internalization
characteristics changes considerably. In our in vitro system
using SHSY5Y cells the peptide functionalized LNCs showed
worse uptake than the non-functionalized ones. In fact, this
observation is in agreement with a previous report (Hirsjarvi
et al., 2013). LNCs are subjected to surface modifications,
including charged molecules (Perrier et al., 2010). Attaching
for instance polysaccharides to the surface of LNCs offers the
possibility of modifying the physicochemical and biological
properties of the core particles. Surface modification of LNCs
by post-insertion of the positively charged amphiphilic (Perrier
et al., 2010) lipochitosan made the LNC surface more rigid, but
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FIGURE 9 | Internalization and subcellular localization of
aTrkB-silica NPs into HEI-OC1 (A–L) cells and VOT-N33 cells (I–P);
(A–D). In HEI-OC1 cells after 1 h of incubation aTrkB-NPs localize in
EEA1 positive endosomes. (A) EEA1 staining; (B) aTrKB-NPs, (C)
Overlay; (D) luminance profile; scale bars 20µm. (E–H) In HEI-OC1 cells
90min after start of application aTrkB-NPs were found in LAMP1 positive
late endosomes/lysosomes. (E) LAMP1 staining; (F) aTrkB-NPs, (G)
Overlay; (H) luminance profile; scale bars 20µm. Panels (I–L) in VOT-N33
cells after 1 h of incubation aTrKB-NPs localize in EEA1 positive
endosomes. (I) EEA1 staining; (J) aTrkB-NPs, (K) Overlay; (L) luminance
profile; scale bars 20µm. Panels (M–P) in VOT-N33 cells 90min after
start of application aTrkB-NPs were found in LAMP1 positive late
endosomes/lysosomes. (M) LAMP1 staining; (N) aTrkB-NPs, (O) Overlay;
(P) luminance profile; scale bars 20µm.
the neutral, higher molecular weighted lipodextran had no effect
on the surface elasticity (Hirsjarvi et al., 2013). Although, these
surface modified LNCs were better captured by the mononuclear
phagocyte system, the neutral and charged molecules did not
influence the in vivo biodistribution properties of LNCs in mice
(Hirsjarvi et al., 2013). In addition, neuronal uptake mechanisms
may not be identical with the mononuclear phagocyte system.
With polymerosomes we found similar results in organotypic
cultures. Here unfunctionalized particles showed an even uptake
throughout the tissue while pattern differed with functionalized
NPs. Here again a preference for the region of the spiral ganglion
was found and appeared to be enriched with the targeting ligand.
Further experiments investigating the kinetics of uptake in
certain cell types would be necessary to prove specifity. However,
adding moieties that can be used to target NPs into different cell
types with high affinity is not an easy task. Surface modification
of NPs often need to be introduced for providing functional
groups that ca be conjugated with the ligand thereby changing
the characteristics in and of themselves. To ensure ligand directed
coupling with correct orientation and desired surface density
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FIGURE 10 | Confocal imaging on rotary cultures of P25 mouse
cochleae treated with aTrkB-silica-NPs. [(A,B) overlay, (A) inset green
fluorescence, scale bars 20 µm] localized predominantly in the mesothelial
covering layer of Reißner’s membrane (RM) and tympanic covering layer cells
underneath the basilar membrane (arrowheads in A). Some staining was
observed within the sensory epithelium (asterisks). In (B) enhanced uptake
was observed within the inner hair cell (arrow). (C) Transmission electron
microscopy of aTrkB-NPs treated cochlea with NPs found in a tympanic
covering layer cell (scale bar 1µm). (D) Confocal projection of a control rotary
culture showing the organ of Corti with Tuj1 positive nerve fibers underneath
inner (IHC) and outer hair cells (OHC)-scale bar 20 µm. PNF, peripheral nerve
fibers; TM, tectorial membrane; SM, scala media; ST, scala tympani; SM, scala
media; SV, scala vestibuli.
may be a problem especially for very small particles (Friedman
et al., 2013).
Antibody grafted NPs also face major challenges such
as high specifity and affinity for target structures on cell
surfaces. Further linker and nanocarrier material must not
lower specific binding. Initial tests whether our antibody surface
modification is functional and contributes both to enhanced
binding and internalization in TrkB positive cells showed that
the surface modification contributed to binding only. TrkB
positive HEI-OC1 cells were exposed to functionalized NPs or
to functionalized NPs and an excess of TrkB antibody inhibiting
antibody-mediated binding of the immuno-NPs. When the
experiment was performed at 4◦C, inhibiting endocytosis,
significantly more NPs were found on cells treated with only
immuno-NPs than on cells treated with both free antibody and
functionalized NPs. However when, the experiment was carried
out at 33◦C the significant difference was lost. This suggests that
the binding of the functionalized NP is significantly determined
by the specific antibody-TrkB interaction while the contribution
of the antibody to the endocytosis of the membrane associated
NP is negligible. This interpretation might be counterintuitive
but it fits to the model of Decuzzi and Ferrari (2007). According
to their model, for a NP the contribution of non-specific
interactions such as electrostatic force to the early stages of
endocytosis is as important as the specific interactions which are
exerted by ligand surface modifications. The herein used 50 nm
silica NP had an average of 3–5 antibodies grafted to the surface;
the larger part of the NP surface was accessible to unspecific
membrane-to-NP interactions. As a consequence, attractive
unspecific interactions between NP and membrane might have
been considerably larger than the specific interactions, thus
governing the membrane wrapping process. Since the formation
of themembrane invagination is the step determining the velocity
in the endocytic process, the avidity of the immuno-conjugated
NP-TrkB interaction might be insufficient to contribute with
significant, specific interactions between NP and cell. It might
appear that under given conditions the unspecific binding of
NP to the cell is more significant for the endocytic uptake than
the antibody-mediated binding. Taken together, this suggests for
the herein used NPs the surface-grafting of TrkB antibodies was
insufficient to significantly contribute to endocytosis of the NP.
A further explanation for the obtained results might be
provided by macropinocytosis as source for “non-specific”
internalization of the immuno-NPs. Since the aTrkB NPs
were composed of the same matrix material as the NPs
used previously (Pritz et al., 2013a), macropinocytosis might
also have contributed substantially to the internalization of
the aTrkB NPs as reported in the this study. In case of
macropinocytosis, large amounts of extracellular liquid are
internalized into the cell. Therefore, the internalization of NPs
by macropinocytosis does not necessarily require membrane
binding of the NPs. A high rate of non-specific ground-level
internalization by macropinocytosis would explain the lacking
difference between the binding and the blocking set-up. A factor
which would lead to an increase in macropinocytosis-dependent
internalization is NP clustering (Canton and Battaglia, 2012).
As the binding and internalization experiments were conducted
under serum-free conditions, only the “blocking” set-up with
its 63-fold antibody excess provided enough soluble protein
to cause protein-mediated NP-aggregation (Monopoli et al.,
2011). An antibody-induced NP agglomeration could have led
to an artificially higher internalization rate under “blocking”
conditions.Moreover, also an excess of the aTrkBNPs itself might
have been responsible for an increased non-specific binding of
the immuno-NPs. The higher the concentration of the NPs, the
higher the possibility for a non-specific pinocytic internalization
by macropinocytosis. These considerations suggest that also a
better control of the discussed experimental parameters as well as
the colloidal stability is necessary to assess the true contribution
of the antibody surface modification to the endocytosis of the
immuno-NPs.
The insufficient contribution of NPs to internalization and
tissue penetration suggest that an optimization of the nanocarrier
system to selectively bind and activate TrkB with specific
uptake in TrkB positive cells is necessary. Since a mismatch
between specific and unspecific NP-to-membrane interactions
is a likely source of error, an increase in specific interaction
strength and a decrease in non-specific interaction would be
beneficial. This can be achieved by increasing the number
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FIGURE 11 | Rolipram-loaded lipid nanocapsules (LNCs) partially
rescue cisplatin-induced apoptosis in postnatal mouse cochlea
cultures (P24). Spiral ganglion neurons (SGN) treated with cisplatin
and rolipram-loaded LNCs exhibit less cleaved caspase 3 (CC3-red
staining) immune reactivity (A) than controls exclusively treated with
cisplatin (D). In the spiral ligament (SL) cisplatin induces increased
CC3 reactivity (J) while additional treatment with rolipram-loaded LNCs
reduced the CC3-reacitivty (G). (A,D,G,J) CC3 immunolabeling;
(B,E,H,K) phalloidine labeling and DAPI staining; (C,F,I,L) bright field.
Scale bar 50µm.
of antibody molecules per NP. Silica NPs expose amino
residues for surface functionalization. The remaining amino
residues might be used for surface PEGylation. This would
efficiently decrease non-specific interactions with the biological
environment. For example, such a polymer brush is thought to
minimize NP-protein-interactions (Vonarbourg et al., 2006a,b;
Monopoli et al., 2011). The polymer coating could prevent non-
specific interactions with the membrane/membrane proteins.
In general a change of the particle type would also be an
approach to solve these problems. LNCs would offer optimal
membrane interaction properties. One the one hand, they
minimize unwanted interactions by a PEG brush. On the other
hand they exhibit a 10-fold higher avidity caused by a higher
number of antibody molecules on the particle surface (Beduneau
et al., 2007, 2008). However, we showed that there were enough
aTrk-NPs or aggregates bound to TrkB positive cells present to
activate neurotrophic signaling. This might partially compensate
the slowing down and impairment of endocytosis as observed
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with unfunctionalized silica NPs (Pritz et al., 2013a). Immuno-
conjugated NPs showed similar trafficking pattern at confocal
level that may pose a threat to important functions in the survival
signaling in SGNs. Thus, (over-) load of silica NPs for cell
types involved in sensorineural survival signaling needs to be
minimized and a strategy for endosomal escape has to be applied
for a use as drug carriers. In conclusion the surface chemistry of
NPs aimed for TrkB-positive SGNs has still to be optimized and
tested to guarantee a functional and specific antibody-based DD
system customized for the SGNs.
Concerning the application of immuno-NPs to the whole-
organ culture of cochleae, consistent results from TEM and
confocal imaging show that the tissue permeation of the
immuno-NPs was insufficient to reach TrkB positive cells
in higher amounts. Antibody contribution to internalization
of the immuno-NP-TrkB-complex is low as shown with our
competitive blocking assay. TrkB is expressed in SGN in adult
human (Liu et al., 2011) and in inner hair cells and neurons
in young adult mice (Bitsche et al., 2011). Although some
aggregation to inner hair cells was found our observations
suggest that the permeation of the aTrkB NPs to those sites
was not quantitative. The lack of tissue permeation might be
caused by the specific physicochemical parameters of the silica
NP. Since it was documented for in vivo experiments with
other particles like LNCs (Zou et al., 2008), polymerosomes and
liposomes (Buckiova et al., 2012) to locate within the cells of
the organ of Corti, it might be necessary to switch to one of
those carrier types. As a consequence, a fundamental change
in the physicochemical properties of the carrier or a change to
another type of nanocarrier is required to reach these TrkB-
positive structures in the cochlea. Another problem for DD via
the RWM into the ear presents the high phagocytic activity of the
mesothelial covering layer cells lining the perilymphatic spaces.
These cells form a loose layer. Like in other body cavities this
cell type is able to phagocyte even bacteria and has function for
antigen presentation (Visser et al., 1996). Strategies to selectively
prevent this phagocytosis or better promote transcytosis toward
endolymphatic compartments may be necessary. Analysis of fluid
spaces in the human cochlea suggests rather easy accessibility for
from scala tympani to SGNs (Rask-Andersen et al., 2006).
DD with targeting ligand NPs for the inner ear remain
complex nevertheless the inner ear may be a good model organ
for this approach with the possibility for local drug delivery
to an organ isolated by a blood-labyrinth-barrier. Schuknecht
was one of the first who experimented with intratympanic drug
administration in the treatment of severe vertigo (Schuknecht,
1956). He reported success in Meniere symptomology with
the intratympanic streptomycin injection but resulted also in
profound hearing loss. However, the efficacy of his approach vs.
systemic drug administration has been confirmed for various
clinical indications. The major site of absorption of drugs is
the RWM, the concentration of the drug in the inner ear
depends greatly on the exposure time and drug concentration.
To overcome rapid clearance by ciliated epithelia in the middle
ear different hydrogels were used to immobilize a drug reservoir
(Paulson et al., 2008). They tested chitosan-glycerophosphate
hydrogels containing dexamethasone or gentamicin in the
murine cochlea on the round window. We also previously
reported permeation and distribution of paramagnetic particles
loaded in an intelligent gel becoming solid at body temperature
(Thaler et al., 2011). A cochlear implant is an artificial hearing
device that can replace damaged hair cells in the cochlea.
To minimize trauma during electrode insertion and reduce
postsurgical inflammation reactions and fibrosis becomes more
and more important especially in context with electro-acoustic
stimulation of the cochlear nerve. Drug eluting electrodes are
currently developed also using hydrogels (Hutten et al., 2014) or
polymeric coatings (Ceschi et al., 2014). These carrier materials
offer also great possibilities for nanocarriers and are already in
use with human applications (Nakagawa et al., 2014).
Kikkawa et al. (2014) tested insulin like growth factor or
heptatocyte growth factor in gelatine hydrogel coated electrodes.
Their findings provide the first evidence that a hydrogel coated,
growth factor-releasing electrode could attenuate insertion
trauma and promote recovery from it. A combination that might
be a DD strategy also for other inner ear damages.
Our experiments with rolipram loaded LNCs proved drug
release by a nanocarrier. The drug delivery mechanism of LNCs
is believed to be dependent on endocytosis and to involve
endosomal escape (Paillard et al., 2010). For lipophilic cargo
a slow and constant release from the LNC and a subsequent
diffusion to the acceptor compartment has been demonstrated
to accomplish subcellular DD with our HEI-OC1 cell line
without the involvement of endocytosis (Bastiat et al., 2013).
In contrast, amphiphilic cargo is confined to the LNC lumen.
While amphiphilic cargo is confined in the surfactant shell of the
LNC, lipophilic molecules are localizing in the lipophilic center of
the LNCs, allowing diffusion of the cargo. Our rolipram loaded
LNC NP in rotary cultures of adult inner ears demonstrate the
bioefficacy of this drug release system to prevent apoptosis caused
by cisplatin in the adult murine inner ear. Previous experiments
could prove that incorporation of rolipram in LNCs increased
the survival of SGNs significantly in in vitro cultures of immature
neurons (Meyer et al., 2012).Without the use of any nanocarriers,
concentration level of rolipram appeared to be very crucial as
demonstrated in Kranz et al. (2014). Our rotary culture system
proved as controllable system for adult inner ear tissue and could
demonstrate this effect for the first time in adult inner ear tissue.
LNCsmay act as an appropriate system to deliver lipophilic drugs
in low doses with a linear release characteristics suitable for inner
ear application and do not feature initial burst release (Lamprecht
et al., 2002). Thus, LNCs are one of the few carrier systems,
which were able to demonstrate actual DD efficiency in the
cochlea so far.
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